Milenko Tanasijevic

Milenko Tanasijevic

Milenko Tanasijevic, M.D., M.B.A.

Advisor, Indi
Director, Brigham and Women’s Hospital & Dana Farber Cancer Institute, Clinical Laboratories
Associate Professor, Harvard Medical School

Dr. Tanasijevic is the Director of the Brigham and Women’s Hospital (BWH) and Dana Farber Cancer Institute (DFCI) Clinical Laboratories and an Associate Professor of Pathology at Harvard Medical School.

The BWH and DFCI clinical laboratories include over forty licensed laboratory sites performing more than 10 million tests annually with combined revenues of over $400 million and featuring state-of-the-art lab automation, advanced molecular diagnostics capabilities, fully integrated specimen bio-repository and a Cardiovascular Biomarker Clinical Trial Laboratory. The BWH Clinical Laboratories were recently recognized by the Institute of Medicine’s Roundtable on Value and Science-Driven Health Care as an example of increased system efficiency through application of Clinical Lab Automation and Lean Process Redesign.

Dr. Tanasijevic completed his residency training in Clinical Pathology at the Brigham and Women’s Hospital in 1993. He became the Director of the DFCI Clinical Laboratories in 1999 and of both the BWH and DFCI Clinical Laboratories in 2002. Dr. Tanasijevic earned his Medical Degree at the University Cyril and Methodius in Macedonia in 1987 and his Masters in Business Administration at the Boston University School of Management in 2004. Dr. Tanasijevic conducted pioneering studies to identify cardiac troponin-I as the major risk stratification biomarker in patients with acute coronary syndromes. He also developed a novel risk stratification model for neonatal respiratory distress syndrome using fetal lung maturity tests. His current research is focused on computerized clinical decision support, laboratory process improvement and total laboratory automation.

Dr. Tanasijevic serves on the College of American Pathologists Instrumentation Committee, CDC / Battelle Laboratory Medicine Best Practices Workgroup and Cardiac Markers Expert Panel, National Quality Forum Clinical Laboratory Steering Committee, and chairs the American Society of Clinical Pathology’s Expert Review Panel. Dr. Tanasijevic is on the Editorial Board of the American Journal of Clinical Pathology and the Journal of Thrombosis and Thrombolysis. He is a co-founder of Cell Imaging Systems Inc., and consults extensively in the field of in vitro diagnostics.

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue